This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gagnon, S. Articles by Tremblay, R. R. Search for Related Content PubMed PubMed Citation Articles by Gagnon, S. Articles by Tremblay, R. R.

American Journal of Pathology, Vol 136, 1147-1152, Copyright © 1990 by American Society for Investigative Pathology

REGULAR ARTICLES

Expression of Zn-alpha 2-glycoprotein and PSP-94 in prostatic adenocarcinoma. An immunohistochemical study of 88 cases

S Gagnon, B Tetu, JY Dube and RR Tremblay
Department of Pathology, L'Hotel-Dieu de Quebec, Canada.

Zn-Alpha 2-Glycoprotein (Zn-Alpha 2-GP) and prostatic secretory protein of 94 amino-acids (PSP-94) were recently isolated from the human prostate. Their expression in benign and malignant well-differentiated and poorly differentiated components of 88 prostates with prostatic adenocarcinomas, and in 25 metastases, was evaluated using polyclonal antibodies developed against these antigens. Zn-Alpha 2-GP was present in benign hyperplastic glands in 91.1% of cases, but in only 40.7% (poorly differentiated component) to 48.5% (well-differentiated component) of prostatic adenocarcinomas, and in 8% of metastases. The expression of PSP-94 was present in 89.3% of benign hyperplastic glands, but in only 50% (well-differentiated adenocarcinoma component) to 57.3% (poorly differentiated component) of prostatic adenocarcinomas and 28% of metastases. The expression of these proteins by the tumor was unrelated to the initial stage and the tumor grade. Because of their low frequency in prostatic adenocarcinomas, especially in metastases, Zn-Alpha 2-GP and PSP-94 appear to have a limited diagnostic usefulness. Further studies are needed, however, to explore other clinical applications of these two new prostatic secretory proteins.

This article has been cited by other articles:

				Md. I. Hassan, A. Waheed, S. Yadav, T. P. Singh, and F. Ahmad Zinc {alpha}2-Glycoprotein: A Multidisciplinary Protein Mol. Cancer Res., June 1, 2008; 6(6): 892 - 906. [Abstract] [Full Text] [PDF]

				J. Lapointe, C. Li, J. P. Higgins, M. van de Rijn, E. Bair, K. Montgomery, M. Ferrari, L. Egevad, W. Rayford, U. Bergerheim, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer PNAS, January 20, 2004; 101(3): 811 - 816. [Abstract] [Full Text] [PDF]

				L. P. Hale, D. T. Price, L. M. Sanchez, W. Demark-Wahnefried, and J. F. Madden Zinc {{alpha}}-2-Glycoprotein Is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer Clin. Cancer Res., April 1, 2001; 7(4): 846 - 853. [Abstract] [Full Text]

				M. G. Walker, W. Volkmuth, E. Sprinzak, D. Hodgson, and T. Klingler Prediction of Gene Function by Genome-Scale Expression Analysis: Prostate Cancer-Associated Genes Genome Res., December 1, 1999; 9(12): 1198 - 1203. [Abstract] [Full Text]

				C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF]